Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05358249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05358249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 24, 2022
Completion date
September 30, 2026
Enrollment
74 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, carcinoma, non-small-cell lung, colorectal cancer, colorectal carcinoma, colorectal neoplasms, colorectal tumors, kras g12c mutant solid tumors, neoplasms, colorectal, non-small cell lung cancer, non-small cell lung carcinoma, nonsmall cell lung cancer